群馬大学 大学院保健学研究科 医学部保健学科

本文ヘジャンプします"
  • キャンパスマップ
  • サイトマップ
  • お問い合わせ
  • アクセスマップ
  • 日本語
  • English

保健学科について / 保健学研究科について

プロフィール 教育と研究 臨床業務、地域・国際貢献 業 績

▌プロフィール

久田 剛志
ひさだ たけし 久田 剛志 Takeshi Hisada リハビリテーション領域 基礎保健学ユニット

現 職
群馬大学大学院保健学研究科 教授

資 格
日本内科学会総合内科専門医、日本呼吸器学会専門医、日本アレルギー学会専門医、日本感染症学会専門医、インフェクションコントロールドクター(ICD)

所属学会
日本内科学会、日本呼吸器学会(代議員)、日本アレルギー学会(代議員)、日本感染症学会(評議員)、日本呼吸ケア・リハビリテーション学会(代議員)、日本リハビリテーション医学会、日本癌学会、日本肺癌学会、日本臨床腫瘍学会、日本結核病学会、日本職業・環境アレルギー学会(評議員、編集委員長)、国際喘息学会日本/北アジア部会(幹事)、ヨーロッパ呼吸器学会(ERS)、米国胸部疾患学会(ATS)

コメント

研究は、喘息やCOPD、間質性肺炎、がん、感染症などの呼吸器疾患の病態解明やその制御をおもなテーマとしています。呼吸器疾患に対するリハビリテーションの有効性に関する検討、脂質メディエーターの呼吸器疾患に対する作用に関する分子生物学的な研究もおこなっています。

▌教育と研究

研究内容

呼吸器疾患、アレルギー疾患を中心に、生理学的、分子生物学的手法を用いて研究をおこなっている。

  1. COPDや間質性肺炎、喘息・アレルギーなどの炎症性疾患に対する脂質メディエーターの働きや呼吸リハビリテーションとの協同作用についての研究
  2. 呼気ガス分析による炎症性呼吸器疾患の病態解析と呼吸リハビリテーションの効果の評価
  3. 炎症性呼吸器疾患に対するω3脂肪酸由来脂質メディエーターの作用に関する研究
教育業務

学部教育
  老年医学、臨床病態学、教養総合科目保健学科
  (医学科)呼吸器内科学、アレルギー学の講義
  (保健学科理学療法専攻)卒業研究の指導

 

大学院教育
  (前期課程:基礎理学療法学特別研究、後期課程:基礎理学・作業療法学特別研究)
   呼吸器疾患に関する高度な基礎知識の教授と研究指導

▌臨床業務、地域・国際貢献

臨床業務

附属病院にて
  ●呼吸器・アレルギー外来
  ●アスベスト外来
  ●肺腫瘍カンファレンス、病棟カンファレンス

地域・国際貢献

群馬県結核審査協議会委員
群馬県アレルギー疾患対策推進協議会委員
日本呼吸器学会和文誌編集委員
日本アレルギー学会「喘息予防・管理ガイドライン2018」作成委員会委員
日本アレルギー学会 臨床アレルギー講習会ワーキンググループ委員
日本職業・環境アレルギー学会「職業性アレルギー疾患診療ガイドライン2016」作成委員会委員

▌業 績

  1. Miura Y, Imai H, Sakurai R, Kaira K, Sunaga N, Minato K, Saito R, Hisada T. The effect of post-progression survival on overall survival among patients with sensitive relapse of small cell lung cancer. Med Oncol. 35, 45, 2018.
  2. Yamaguchi K, Yamaguchi A, Kashiwagi C, Sawada Y, Taguchi K, Umetsu K, Oshima K, Uchida M, Suzuki M, Kono S, Takemura M, Masubuchi H, Kitahara S, Hara K, Maeno T, Motegi SI, Muro Y, Sakairi T, Hisada T, Kurabayashi M. Differential clinical features of patients with clinically amyopathic dermatomyositis who have circulating anti-MDA5 autoantibodies with or without myositis-associated autoantibodies. Respir Med. 140, 1-5, 2018.
  3. Bao H, Bai T, Takata K, Yokobori T, Ohnaga T, Hisada T, Maeno T, Bao P, Yoshida T, Kumakura Y, Honjo H, Sakai M, Sohda M, Fukuchi M, Altan B, Handa T, Ide M, Miyazaki T, Ogata K, Oyama T, Shimizu K, Mogi A, Asao T, Shirabe K, Kuwano H, Kaira K. High expression of carcinoembryonic antigen and telomerase reverse transcriptase in circulating tumor cells is associated with poor clinical response to the immune checkpoint inhibitor nivolumab. Oncol Lett. 15, 3061-3067, 2018.
  4. Miura Y, Kaira K, Sakurai R, Sunaga N, Saito R, Hisada T, Yamada M. High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin. Lung Cancer. 115, 42-48, 2018.
  5. Hisada T, Aoki-Saito H, Koga Y. Are specialized pro-resolving mediators promising therapeutic agents for severe bronchial asthma? J Thorac Dis. 9, 4266-4269, 2017.
  6. Sakurai R, Tomizawa Y, Yoshii A, Miura Y, Tsurumaki H, Kaira K, Sunaga N, Kawashima O, Hisada T, Yamada M, Saito R. A phase II study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA non-small cell lung cancer. Cancer Chemother Pharmacol. 81, 103-109, 2018
  7. Kaira K, Higuchi T, Naruse I, Arisaka Y, Tokue A, Altan B, Suda S, Mogi A, Shimizu K, Sunaga N, Hisada T, Kitano S, Obinata H, Yokobori T, Mori K, Nishiyama M, Tsushima Y, Asao T. Metabolic activity by 18F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC.

Eur J Nucl Med Mol Imaging. 45, 56-66, 2018.

  1. Miura Y, Kaira K, Sakurai R, Imai H, Tomizawa Y, Sunaga N, Minato K, Hisada T, Oyama T, Yamada M. Prognostic effect of class III β-tubulin and Topoisomerase-II in patients with advanced thymic carcinoma who received combination chemotherapy, including taxanes or topoisomerase-II inhibitors. Oncol Lett. 14, 2369-2378, 2017.
  2. Kaira K, Yanagitani N, Sunaga N, Imai H, Ono A, Koga Y, Hisada T, Ishizuka T, Yamada M. Prospective exploratory study of gemcitabine and S-1 against elderly patients with advanced non-small cell lung cancer. Oncol Lett. 14, 1123-1128, 2017.
  3. Miura Y, Kaira K, Sakurai R, Imai H, Tomizawa Y, Sunaga N, Minato K, Hisada T, Oyama T, Yamada M. High expression of GRP78/BiP as a novel predictor of favorable outcomes in patients with advanced thymic carcinoma. Int J Clin Oncol. 22, 872-879, 2017.
  4. Kotake M, Miura Y, Imai H, Mori K, Sakurai R, Kaira K, Tomizawa Y, Minato K, Saito R, Hisada T. Post-Progression Survival Associated with Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Receiving Docetaxel Monotherapy as Second-Line Chemotherapy. Chemotherapy. 62, 205-213, 2017.
  5. Imai H, Kuwako T, Kaira K, Masuda T, Miura Y, Seki K, Sakurai R, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Evaluation of gefitinib efficacy according to body mass index, body surface area, and body weight in patients with EGFR-mutated advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 79, 497-505, 2017.
  6. Kaira K, Tomizawa Y, Imai H, Sakurai R, Matsuura M, Yoshii A, Ochiai M, Kotake M, Ebara T, Saitoh JI, Sunaga N, Minato K, Saito R, Hisada T. Phase I study of nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 79, 165-171, 2017.
  7. Kaira K, Higuchi T, Sunaga N, Arisaka Y, Hisada T, Tominaga H, Oriuchi N, Asao T, Tsushima Y, Yamada M. Usefulness of 18F-α-Methyltyrosine PET for Therapeutic Monitoring of Patients with Advanced Lung Cancer. Anticancer Res. 36, 6481-6490, 2016.
  8. Koga Y, Satoh T, Kaira K, Koka M, Hisada T, Hirato J, Altan B, Yatomi M, Ono A, Kamide Y, Shimizu Y, Aoki-Saito H, Tsurumaki H, Shimizu K, Mogi A, Ishizuka T, Yamada M, Dobashi K. Elemental and immunohistochemical analysis of the lungs and hilar lymph node in a patient with asbestos exposure, a pilot study. Environ Health Prev Med. 21, 492-500, 2016.
  9. Koga Y, Hisada T, Ishizuka T, Utsugi M, Ono A, Yatomi M, Kamide Y, Aoki-Saito H, Tsurumaki H, Dobashi K, Yamada M.CREB regulates TNF-α-induced GM-CSF secretion via p38 MAPK in human lung fibroblasts. Allergol Int. 65, 406-413, 2016.
  10. Protective Role of Proton-Sensing TDAG8 in Lipopolysaccharide-Induced Acute Lung Injury. Tsurumaki H, Mogi C, Aoki-Saito H, Tobo M, Kamide Y, Yatomi M, Sato K, Dobashi K, Ishizuka T, Hisada T, Yamada M, Okajima F. Int J Mol Sci. 16, 28931-42, 2015.
  11. Yatomi M, Hisada T, Ishizuka T, Koga Y, Ono A, Kamide Y, Seki K, Aoki-Saito H, Tsurumaki H, Sunaga N, Kaira K, Dobashi K, Yamada M, Okajima F. 17(R)-resolvin D1 ameliorates bleomycin-induced pulmonary fibrosis in mice. Physiol Rep. 3, pii: e12628, 2015.
  12. Kaira K, Sunaga N, Imai H, Kamide Y, Koga Y, Ono A, Kuwako T, Masuda T, Hisada T, Ishizuka T, Yamada M. Phase I dose escalation study of amrubicin plus paclitaxel in previously treated advanced non-small cell lung cancer. Int J Clin Oncol. 21, 240-247, 2015.
  13. Kuwako T, Imai H, Masuda T, Miura Y, Seki K, Yoshino R, Kaira K, Utsugi M, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Ishizuka T, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations. Cancer Chemother Pharmacol. 76, 761-9, 2015.
  14. Kamide Y, Ishizuka T, Tobo M, Tsurumaki H, Aoki H, Mogi C, Nakakura T, Yatomi M, Ono A, Koga Y, Sato K, Hisada T, Dobashi K, Yamada M, Okajima F. Acidic environment augments FcεRI-mediated production of IL-6 and IL-13 in mast cells. Biochem Biophys Res Commun. 464, 949-55, 2015.
  15. Masuda T, Imai H, Kuwako T, Miura Y, Yoshino R, Kaira K, Shimizu K, Sunaga N, Tomizawa Y, Ishihara S, Mogi A, Hisada T, Minato K, Takise A, Saito R, Yamada M. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations. Clin Transl Oncol. 17, 702-9, 2015.
  16. Ishizuka T, Hisada T, Kamide Y, Aoki H, Seki K, Honjo C, Sakai H, Kadowaki M, Umeda Y, Morikawa M, Anzai M, Ameshima S, Ishizaki T, Dobashi K, Yamada M, Kusano M. The effects of concomitant GERD, dyspepsia, and rhinosinusitis on asthma symptoms and FeNO in asthmatic patients taking controller medications. J Asthma Allergy. 7, 131-9, 2014.
  17. Kotake M, Sato K, Mogi C, Tobo M, Aoki H, Ishizuka T, Sunaga N, Imai H, Kaira K, Hisada T, Yamada M, Okajima F. Acidic pH increases cGMP accumulation through the OGR1/phospholipase C/Ca(2+)/neuronal NOS pathway in N1E-115 neuronal cells. Cell Signal. 26, 2326-32, 2014.
  18. Ishizuka T, Hisada T, Hatori M, Koike A, Hanabuchi K, Matsuzaki S, Kamide Y, Utsugi M, Aoki H, Yoshino R, Yanagitani N, Koga Y, Ono A, Kaira K, Sunaga N, Dobashi K, Tsuburai T, Akiyama K, Yamada M, Suzuki K, Mori M. Safety and efficacy of high-dose leukocytapheresis in patients with refractory asthma. Inflamm Res. 63(9):789-96, 2014.
  19. Sunaga N, Kaira K, Tomizawa Y, Shimizu K, Imai H, Takahashi G, Kakegawa S, Ohtaki Y, Nagashima T, Kasahara N, Kawashima O, Hisada T, Saito R, Yamada M. Clinicopathological and prognostic significance of interleukin-8 expression and its relationship to KRAS mutation in lung adenocarcinoma. Br J Cancer. 110, 2047-53, 2014.
  20. Aoki H, Mogi C, Hisada T, Nakakura T, Kamide Y, Ichimonji I, Tomura H, Tobo M, Sato K, Tsurumaki H, Dobashi K, Mori T, Harada A, Yamada M, Mori M, Ishizuka T, Okajima F. Proton-sensing ovarian cancer G protein-coupled receptor 1 on dendritic cells is required for airway responses in a murine asthma model. PLoS One. 8, e79985, 2013.
  21. Kaira K, Tomizawa Y, Yoshino R, Yoshii A, Matsuura M, Iwasaki Y, Koga Y, Ono A, Nishioka M, Kamide Y, Hisada T, Ishizuka T, Shirai K, Ebara T, Saitoh J, Nakano T, Sunaga N. Phase II study of oral S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Lung Cancer. 82, 449-54, 2013.
  22. Seki K, Hisada T, Kawata T, Kamide Y, Dobashi K, Yamada M, Mori M, Okajima F, Ishizuka T. Oxidative stress potentially enhances FcεRI-mediated leukotriene C4 release dependent on the late-phase increase of intracellular glutathione in mast cells. Biochem Biophys Res Commun. 439, 357-62, 2013.
  23. Kaira K, Tomizawa Y, Yoshino R, Miura Y, Yoshii A, Iwasaki Y, Koga Y, Ono A, Hisada T, Minato K, Sato K, Kazama T, Ishihara S, Kohyama K, Fueki N, Saito R, Sunaga N. Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. Lung Cancer. 82, 103-8, 2013.
  24. Ishizuka T, Matsuzaki S, Aoki H, Yatomi M, Kamide Y, Hisada T, Tsuburai T, Dobashi K, Ohshima K, Akiyama K, Mori M. Prevalence of asthma symptoms based on the European Community Respiratory Health Survey questionnaire and FENO in university students: gender differences in symptoms and FENO. Allergy Asthma Clin Immunol. 7, 15, 2011.
  25. Matsuzaki S, Ishizuka T, Yamada H, Kamide Y, Hisada T, Ichimonji I, Aoki H, Yatomi M, Komachi M, Tsurumaki H, Ono A, Koga Y, Dobashi K, Mogi C, Sato K, Tomura H, Mori M, Okajima F. Extracellular acidification induces connective tissue growth factor production through proton-sensing receptor OGR1 in human airway smooth muscle cells. Biochem Biophys Res Commun. 413, 499-503, 2011.
  26. Kamide Y, Utsugi M, Dobashi K, Ono A, Ishizuka T, Hisada T, Koga Y, Uno K, Hamuro J, Mori M. Intracellular glutathione redox status in human dendritic cells regulates IL-27 production and T-cell polarization.Allergy. 66, 1183-92, 2011.
  27. Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M, Endo K. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-α-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol. 37, 911-6, 2010.
  28. Matsuzaki S, Ishizuka T, Hisada T, Aoki H, Komachi M, Ichimonji I, Utsugi M, Ono A, Koga Y, Dobashi K, Kurose H, Tomura H, Mori M, Okajima F. Lysophosphatidic acid inhibits CC chemokine ligand 5/RANTES production by blocking IRF-1-mediated gene transcription in human bronchial epithelial cells. J Immunol. 185, 4863-72, 2010.
  29. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in surgically resectable stage III non-small cell lung cancer. Exp Ther Med. 1, 799-808, 2010.
  30. Aoki H, Hisada T, Ishizuka T, Utsugi M, Ono A, Koga Y, Sunaga N, Nakakura T, Okajima F, Dobashi K, Mori M. Protective effect of resolvin E1 on the development of asthmatic airway inflammation. Biochem Biophys Res Commun. 400, 128-33, 2010.
  31. Ichimonji I, Tomura H, Mogi C, Sato K, Aoki H, Hisada T, Dobashi K, Ishizuka T, Mori M, Okajima F. Extracellular acidification stimulates IL-6 production and Ca(2+) mobilization through proton-sensing OGR1 receptors in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 299, L567-77, 2010.
  32. Utsugi M, Dobashi K, Ono A, Ishizuka T, Hisada T, Koga Y, Shimizu Y, Kawata T, Matsuzaki S, Aoki H, Kamide Y, Mori M. JNK1 and JNK2 differently regulate IL-12 production in THP-1 macrophage cells. Cytokine. 51, 127-31, 2010.
  33. Kuribayashi S, Kusano M, Kawamura O, Shimoyama Y, Maeda M, Hisada T, Ishizuka T, Dobashi K, Mori M. Mechanism of gastroesophageal reflux in patients with obstructive sleep apnea syndrome. Neurogastroenterol Motil. 22, 611-e172, 2010.
  34. Kaira K, Sunaga N, Tomizawa Y, Yanagitani N, Shimizu K, Imai H, Utsugi M, Iwasaki Y, Iijima H, Tsurumaki H, Yoshii A, Fueki N, Hisada T, Ishizuka T, Saito R, Mori M. A phase II study of amrubicin, a synthetic 9-aminoanthracycline, in patients with previously treated lung cancer. Lung Cancer. 69, 99-104, 2010.
  35. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Kamide Y, Ishizuka T, Kanai Y, Nakajima T, Mori M. CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases. Ann Surg Oncol. 16, 3473-81, 2009.
  36. Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Iwasaki Y, Shimizu K, Iijima H, Tsurumaki H, Tomizawa Y, Hisada T, Ishizuka T, Saito R, Mori M. Phase 2 study of S-1 plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 68, 253-7, 2010.
  37. Utsugi M, Dobashi K, Ono A, Ishizuka T, Matsuzaki S, Hisada T, Shimizu Y, Kawata T, Aoki H, Kamide Y, Mori M. PI3K p110beta positively regulates lipopolysaccharide-induced IL-12 production in human macrophages and dendritic cells and JNK1 plays a novel role. J Immunol. 182, 5225-31, 2009.
  38. Hisada T, Ishizuka T, Aoki H, Mori M. Resolvin E1 as a novel agent for the treatment of asthma. Expert Opin Ther Targets. 13, 513-22, 2009.
  39. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol. 99, 433-8, 2009.
  40. Imai H, Sunaga N, Kaira K, Kawashima O, Yanagitani N, Sato K, Tomizawa Y, Hisada T, Ishizuka T, Hirato J, Saito R, Nakajima T, Mori M. Clinicopathological features of patients with bronchial-associated lymphoid tissue lymphoma. Intern Med. 48, 301-6, 2009.
  41. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Nakajima T, Mori M. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer. 66, 120-6, 2009.
  42. Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer. Cancer Sci. 100, 753-8, 2009.
  43. Ono A, Utsugi M, Masubuchi K, Ishizuka T, Kawata T, Shimizu Y, Hisada T, Hamuro J, Mori M, Dobashi K. Glutathione redox regulates TGF-beta-induced fibrogenic effects through Smad3 activation. FEBS Lett. 583, 357-62, 2009.
  44. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci. 100, 248-54, 2009.
  45. Kaira K, Oriuchi N, Shimizu K, Ishikita T, Higuchi T, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Evaluation of thoracic tumors with (18)F-FMT and (18)F-FDG PET-CT: a clinicopathological study. Int J Cancer. 124, 1152-60, 2009.
  46. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. Cancer Sci. 99, 2380-6, 2009.
  47. Ishizuka T, Hisada T, Aoki H, Mori M. Resolvin E1: a novel lipid mediator in the resolution of allergic airway inflammation. Expert Rev Clin Immunol. 4, 669-72, 2008.
  48. Kaira K, Sunaga N, Yanagitani N, Kawata T, Utsugi M, Shimizu K, Ebara T, Kawamura H, Nonaka T, Ishikawa H, Sakurai H, Suga T, Hara K, Hisada T, Ishizuka T, Nakano T, Mori M. Phase I study of oral S-1 plus Cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 75, 109-14, 2008.
  49. Kaira K, Ishizuka T, Tanaka H, Tanaka Y, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Mori M. Lung cancer producing granulocyte colony-stimulating factor and rapid spreading to peritoneal cavity. J Thorac Oncol. 3, 1054-5, 2008.
  50. Kaira K, Sunaga N, Yanagitani N, Aoki H, Kawata T, Utsugi M, Shimizu Y, Shimizu K, Hisada T, Ishizuka T, Mori M. Phase I trial of oral S-1 plus gemcitabine in elderly patients with nonsmall cell lung cancer. Anticancer Drugs. 19, 289-94, 2008.
  51. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Kawashima O, Iijima H, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. Expression of L-type amino acid transporter 1 (LAT1) in neuroendocrine tumors of the lung. Pathol Res Pract. 204, 553-61, 2008.
  52. Utsugi M, Ishizuka T, Hisada T, Sato K, Ishizuka T, Dobashi K, Mori M. Hypoxemia with high alveolar-arterial oxygen gradient but no lung involvement in a patient with Churg-Strauss syndrome: case report. Int J Immunopathol Pharmacol. 21, 251-3, 2008.
  53. Zhao JJ, Shimizu Y, Dobashi K, Kawata T, Ono A, Yanagitani N, Kaira K, Utsugi M, Hisada T, Ishizuka T, Mori M. The relationship between oxidative stress and acid stress in adult patients with mild asthma. J Investig Allergol Clin Immunol. 18, 41-5, 2008.
  54. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer. 98, 742-8, 2008.
  55. Aoki H, Hisada T, Ishizuka T, Utsugi M, Kawata T, Shimizu Y, Okajima F, Dobashi K, Mori M. Resolvin E1 dampens airway inflammation and hyperresponsiveness in a murine model of asthma. Biochem Biophys Res Commun. 367, 509-15, 2008.
  56. Kaira K, Sunaga N, Yanagitani N, Hisada T, Ishizuka T, Mori M. Pseudomesotheliomatous adenocarcinoma of the lung with synchronous gastric and esophageal cancer. Australas Radiol. 51 Suppl:B265-7, 2007.
  57. Ishizuka T, Hisada T, Aoki H, Yanagitani N, Kaira K, Utsugi M, Shimizu Y, Sunaga N, Dobashi K, Mori M. Gender and age risks for hoarseness and dysphonia with use of a dry powder fluticasone propionate inhaler in asthma. Allergy Asthma Proc. 28, 550-6, 2007.
  58. Shimizu Y, Dobashi K, Hisada T, Ono A, Todokoro M, Iijima H, Utsugi M, Kakegawa S, Iizuka K, Ishizuka T, Morikawa A, Mori M. Acute impact of volcanic ash on asthma symptoms and treatment. Int J Immunopathol Pharmacol. 20, 9-14, 2007.
  59. Kaira K, Oriuchi N, Otani Y, Shimizu K, Tanaka S, Imai H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Dobashi K, Kanai Y, Endou H, Nakajima T, Endo K, Mori M. Fluorine-18-alpha-methyltyrosine positron emission tomography for diagnosis and staging of lung cancer: a clinicopathologic study. Clin Cancer Res. 13, 6369-78, 2007.
  60. Sunaga N, Oriuchi N, Kaira K, Yanagitani N, Tomizawa Y, Hisada T, Ishizuka T, Endo K, Mori M. Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer. Lung Cancer. 59, 203-10, 2008.
  61. Koike Y, Hisada T, Utsugi M, Ishizuka T, Shimizu Y, Ono A, Murata Y, Hamuro J, Mori M, Dobashi K. Glutathione redox regulates airway hyperresponsiveness and airway inflammation in mice. Am J Respir Cell Mol Biol. 37, 322-9, 2007.
  62. Kaira K, Oriuchi N, Otani Y, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Endo K, Mori M. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients. Chest. 131, 1019-27, 2007.
  63. Shimizu Y, Dobashi K, Zhao JJ, Kawata T, Ono A, Yanagitani N, Kaira K, Utsugi M, Hisada T, Ishizuka T, Mori M. Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. Respiration. 74, 558-64, 2007.
  64. Sunaga N, Tomizawa Y, Yanagitani N, Iijima H, Kaira K, Shimizu K, Tanaka S, Suga T, Hisada T, Ishizuka T, Saito R, Dobashi K, Mori M. Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy. Lung Cancer. 56, 383-9, 2007.
  65. Kaira K, Sunaga N, Yanagitani N, Imai H, Utsugi M, Shimizu Y, Iijima H, Tomizawa Y, Hisada T, Ishizuka T, Saito R, Mori M. A phase I dose-escalation study of S-1 plus carboplatin in patients with advanced non-small-cell lung cancer. Anticancer Drugs. 18, 471-6, 2007.
  66. Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Hisada T, Mori M. Effective combination chemotherapy of carboplatin and paclitaxel in the treatment of a recurrent small-cell lung cancer patient. Gan To Kagaku Ryoho. 34, 225-7, 2007.
  67. Kaira K, Tsuchiya S, Sunaga N, Yanagitani N, Watanabe S, Imai H, Hisada T, Ishizuka T, Saito R, Mori M. A phase I dose escalation study of weekly docetaxel and carboplatin in elderly patients with nonsmall cell lung cancer. Am J Clin Oncol. 30, 51-6, 2007.
  68. Kaira K, Ishizuka T, Yanagitani N, Sunaga N, Hisada T, Mori M. Value of FDG positron emission tomography in monitoring the effects of therapy in progressive pulmonary sarcoidosis. Clin Nucl Med. 32, 114-6, 2007.
  69. Utsugi M, Dobashi K, Ishizuka T, Kawata T, Hisada T, Shimizu Y, Ono A, Mori M. Rac1 negatively regulates lipopolysaccharide-induced IL-23 p19 expression in human macrophages and dendritic cells and NF-kappaB p65 trans activation plays a novel role. J Immunol. 177, 4550-7, 2007.
  70. Shimizu Y, Kuwabara H, Ono A, Higuchi S, Hisada T, Dobashi K, Utsugi M, Mita Y, Mori M. Intracellular Th1/Th2 balance of pulmonary CD4(+) T cells in patients with active interstitial pneumonia evaluated by serum KL-6. Immunopharmacol Immunotoxicol. 28, 295-304, 2006.
  71. Ishizuka T, Kawata T, Shimizu Y, Utsugi M, Endou K, Hisada T, Dobashi K, Nakazawa T, Mori M. Safety and efficacy of extracorporeal granulocyte and monocyte adsorption apheresis in patients with severe persistent bronchial asthma. Inflammation. 29, 9-16, 2005.
  72. Shimizu Y, Dobashi K, Mita Y, Endou K, Moriya S, Osano K, Koike Y, Higuchi S, Yabe S, Utsugi M, Ishizuka T, Hisada T, Nakazawa T, Mori M. DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity. Tuberculosis (Edinb). 86, 374-81, 2006.
  73. Kawata T, Ishizuka T, Tomura H, Hisada T, Dobashi K, Tsukagoshi H, Ishiwara M, Kurose H, Mori M, Okajima F. Sphingosine 1-phosphate inhibits migration and RANTES production in human bronchial smooth muscle cells. Biochem Biophys Res Commun. 331, 640-7, 2005.
  74. Ishizuka T, Yoshii A, Hisada T, Tsukagoshi H, Okayama Y, Iizuka K, Dobashi K, Nakazawa T, Mori M. Effects of fluticasone propionate on bone mineral density in patients with persistent bronchial asthma. Intern Med. 41, 798-804, 2002.
  75. Ishizuka T, Ishizuka T, Iwamae S, Hisada T, Okayama Y, Tsukagoshi H, Dobashi K, Mori M. Interleukin-5 messenger RNA expression in peripheral blood mononuclear cells from patients with bronchial asthma and eosinophilia. Allergy Asthma Proc. 23, 175-9, 2002.
  76. Mak JC, Hisada T, Salmon M, Barnes PJ, Chung KF. Glucocorticoids reverse IL-1beta-induced impairment of beta-adrenoceptor-mediated relaxation and up-regulation of G-protein-coupled receptor kinases. Br J Pharmacol. 135, 987-96, 2002.
  77. Tsukagoshi H, Shimizu Y, Kawata T, Hisada T, Shimizu Y, Iwamae S, Ishizuka T, Iizuka K, Dobashi K, Mori M. Atrial natriuretic peptide inhibits tumor necrosis factor-alpha production by interferon-gamma-activated macrophages via suppression of p38 mitogen-activated protein kinase and nuclear factor-kappa B activation. Regul Pept. 99, 21-9, 2001.
  78. Salmon M, Liu YC, Mak JC, Rousell J, Huang TJ, Hisada T, Nicklin PL, Chung KF. Contribution of upregulated airway endothelin-1 expression to airway smooth muscle and epithelial cell DNA synthesis after repeated allergen exposure of sensitized Brown-Norway rats. Am J Respir Cell Mol Biol. 23, 618-25, 2001.
  79. Tsukagoshi H, Shimizu Y, Iwamae S, Hisada T, Ishizuka T, Iizuka K, Dobashi K, Mori M. Evidence of oxidative stress in asthma and COPD: potential inhibitory effect of theophylline. Respir Med. 94, 584-8, 2000.
  80. Hisada T, Adcock IM, Nasuhara Y, Salmon M, Huang TJ, Barnes PJ, Chung KF. Inhibition of ozone-induced lung neutrophilia and nuclear factor-kappaB binding activity by vitamin A in rat. Eur J Pharmacol. 377, 63-8, 1999.
  81. Hisada T, Salmon M, Nasuhara Y, Chung KF. Cysteinyl-leukotrienes partly mediate eotaxin-induced bronchial hyperresponsiveness and eosinophilia in IL-5 transgenic mice. Am J Respir Crit Care Med. 160, 571-5, 1999.
  82. Tsukagoshi H, Shimizu Y, Horie T, Fukabori Y, Shimizu Y, Iwamae S, Hisada T, Ishizuka T, Iizuka K, Dobashi K, Mori M. Regulation by interleukin-1beta of gene expression of bradykinin B1 receptor in MH-S murine alveolar macrophage cell line. Biochem Biophys Res Commun. 259, 476-82., 1999.
  83. Hisada T, Hellewell PG, Teixeira MM, Malm MG, Salmon M, Huang TJ, Chung KF. alpha4 integrin-dependent eotaxin induction of bronchial hyperresponsiveness and eosinophil migration in interleukin-5 transgenic mice. Am J Respir Cell Mol Biol. 20, 992-1000, 1999.
  84. Iwamae S, Tsukagoshi H, Hisada T, Uno D, Mori M. A possible involvement of oxidative lung injury in endotoxin-induced bronchial hyperresponsiveness to substance P in guinea pigs. Toxicol Appl Pharmacol. 151, 245-53., 1998.
  85. Uno D, Tsukagoshi H, Hisada T, Iwamae S, Mori M. Effects of the calcium ionophore A23187 on airway responsiveness to histamine and substance P in guinea pigs. Inflamm Res. 46, 108-13, 1997.
  86. Ishizuka T, Morita K, Hisada T, Ishizuka T, Ando S, Adachi M, Dobashi K, Mori M. The direct effect of interferon-gamma on human eosinophilic leukemia cell lines: the induction of interleukin-5 mRNA and the presence of an interferon-gamma receptor. Inflammation. 20, 151-63, 1996.
  87. Ishizuka T, Hirata I, Adachi M, Kurimoto F, Hisada T, Dobashi K, Mori M. Effects of interferon-gamma on cell differentiation and cytokine production of a human monoblast cell line, U937. Inflammation. 19, 627-36, 1995.
  88. Kurosawa M, Hisada T, Ishizuka T. Effect of phospholipase A2 inhibitor ONO-RS-082 on substance P-induced histamine release from rat peritoneal mast cells. Int Arch Allergy Immunol. 97, 226-8., 1992.